Connexion
M'inscrire

Votre recherche

Filtres

Project précédent
Projet suivant
Nous verifions auprès de chaque centre si des nouvelles informations sont disponibles

5/9/1309/2020-Nut

To study the effects of mango ingestion in t2dm and non-diabetic subjects.
Source : Importé depuis le centre

Référence clinicaltrials.gov: NCT06055582
Insulin resistance
body composition
glycemic index
Source : Importé depuis le centre
Normoglycemia
T2DM (Type 2 Diabetes Mellitus)
Recrutement fermé
Dernière modification : 2023/10/19

Population cible

Condition médicale (spécialité visée)

Choix aire thérapeutique

Normoglycemia

T2DM (Type 2 Diabetes Mellitus)

Source : Importé depuis le centre

Profil des participants

Sexe(s) des participants

All

Source : Importé depuis le centre

Critères de sélection

Critères d'inclusion

Inclusion Criteria:

-For patients with diabetes: Stable glycemic control on metformin or sulfonylurea for past 3 months and without any major complications and HbA1C less than 8%

Exclusion Criteria:

Acute infections and advanced end-organ damage
History of hepatitis or pancreatitis, abnormal liver and renal functions
Recent (<3 months) changes in weight
Any known allergy to mangoes and bread
Subjects with hypothyroidism
On any drug causing weight gain or weight loss.

Source : Importé depuis le centre

Thérapie ou Intervention proposée

Cohortes
Nom Condition médicale Traitement État du recrutement
Treatment - Mango Donnée non disponible Subjects in mango group will be further randomized into three different groups. Each group will be tested on a different variety of mango.
  • Inconnu
  • Controlled- Bread Donnée non disponible Subjects in bread group were given 81g (3 slices) harvest gold white bread as standard food in raw form.
  • Inconnu
  • Treatment - Mango
    État du recrutement
    unknown
    Controlled- Bread
    État du recrutement
    unknown
    Données à jour depuis : 19 octobre 2023

    Description de l'étude

    Résumé de l'étude

    T2DM patient will be recruited from endocrine OPD

    Clinical History and Examination:

    General Physical Examination:

    Height (cm)
    weight (kg)
    BMI (kg/m2)
    Blood Pressure (mmHg)

    Anthropometry: Circumferences and skinfold thickness will be recorded for the patients in the following manner.

    Circumferences:

    Waist circumference (cm)
    Hip circumference (cm)
    Mid-arm circumference (cm)
    Mid-thigh circumference (cm)

    Skin fold thickness: Skin fold thickness will be measured by using (LANGE skin fold calipers) (to nearest of 1 mm) at the following sites

    Biceps (mm)
    Triceps (mm)
    Thigh (mm)
    Calf (mm)
    Sub scapular (mm)
    Supra-iliac (mm)
    Anterior axillary fold. (mm)

    Biochemical Test: The biochemical analysis will be done using ELISA kit or commercially available kits

    Blood glucose (mg/dL)
    HbA1c (%)
    Serum insulin (μIU/mL)
    Total Cholestrol (mg/dl)
    Triglyceride (mg/dl)
    Fructosamine (umol/L)
    Adiponectin (µg/ml) -- HOMA-IR
    Body Composition Analysis (TANITA)

    Source : Importé depuis le centre

    Phase I: Exploratory Acute Phase- Stratified randomized study

    Study population: 2 groups; patients with T2DM and non-diabetic subjects n=45 (20 T2DM subject, 25 non-diabetic subjects).
    Study groups: 3 groups; OGTT (n=5), mango (n=30), bread (n=10) Subjects in mango group will be further randomized into three different groups. Each group will be tested on a different variety of mango.

    Procedure for Phase I:

    After measuring baseline glucose level on empty stomach, three groups will be given their respective standardized food item and blood samples will be drawn every half an hour upto 2 hours of ingestion at (minutes): 0, 30, 60, 90 and 120. Fingertip capillary blood will be used for the estimation of blood glucose using a glucometer of contour brand.

    Phase II: Exploratory Sub-Acute Phase- Two randomized cross over study

    Study population: 2 groups; patients with T2DM and non-diabetic subjects, n=50 (25 in each study population group)
    Study groups: 2 groups; mango (n=30), bread (n=20) Subjects in mango group will be further randomized into three different groups. Each group will be tested on a different variety of mango.

    Procedure for Phase II:

    Continuous glucose monitoring system (CGMS): It will be affixed for 3 days.
    The research team will be contacting the study subjects every day for any discomfort due to CGMS device or diet.
    On day 4 study subjects will be called to the study site and CGMS will be removed and data will be transferred to the study records.
    Study subjects will be asked to maintain a food diary and record the foods consumed during the entire period of 3 days.
    The subjects will also be asked to fill questionnaire of dietary assessment on Day 1 and Day 4 for per schedule of assessments.

    Phase III: Confirmatory Chronic Phase- Randomized controlled parallel arm study

    Study population: patients with T2DM, n=35
    Study groups: 2 groups; mango (n=20), bread (n=15) Subjects in mango group will be further randomized into two different groups. Each group will be tested on a different variety of mango.

    Procedure for Phase III:

    Subjects will be given glucometers and will be asked to monitor blood glucose at fasting state and after standard breakfast meal at baseline, at day 30 and day 60 in both the study groups. The intermediate term effect of mango consumption and bread consumption will be assessed at baseline and at day 60 in terms of following investigations:

    Dietary assessment
    Physical activity (PA) assessment (GPAQ)
    Blood pressure
    Anthropometry measures
    Body composition
    Biochemical investigations

    Source : Importé depuis le centre

    Sites

    Centres participants

      1 centres
    • FORTIS CDOC HOSPITAL

      New delhi

      DELHI, INDIA

      Recrutement local
      État du recrutement: FERMÉ

    Dernière modification : 19 octobre 2023
    Données à jour depuis : 19 oct.
    Origine des données : clinicaltrials.gov
    Référence clinicaltrials.gov: NCT06055582